Genprex (GNPX) Enterprise Value (2016 - 2026)
Genprex (GNPX) posted quarterly Enterprise Value of -$18.0 million for Q1 2026, down 420.4% year-over-year from $5.6 million in Q1 2025, and down 130.49% quarter-over-quarter from -$7.8 million in Q4 2025.
Genprex (GNPX) Enterprise Value (2016 - 2026) Analysis & Trends
Genprex's Enterprise Value history runs 11 years deep, the most recent figure standing at -$18.0 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 420.4% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at -$18.0 million (down 420.4% YoY), while the FY2025 annual figure was -$7.8 million, down 388.92% from the prior year.
- Enterprise Value for Q1 2026 stood at -$18.0 million, down from -$7.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$1.1 million in Q3 2025, with the low at -$34.6 million in Q1 2022.
- The 5-year median for Enterprise Value is -$8.2 million (2024), against an average of -$11.9 million.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value jumped 87.29% in 2024, then plunged 420.4% in 2026.
- Genprex's Enterprise Value stood at -$21.0 million in 2022, then soared by 67.85% to -$6.7 million in 2023, then surged by 76.23% to -$1.6 million in 2024, then tumbled by 388.92% to -$7.8 million in 2025, then plunged by 130.49% to -$18.0 million in 2026.
- Business Quant data shows GNPX's Enterprise Value at -$18.0 million in Q1 2026, -$7.8 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Genprex | 1.89 Mn | -13.27 Mn | - | -15.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.05 Mn |
| Dec 31, 2025 | -7.83 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.35 Mn |
| Mar 31, 2025 | -3.47 Mn |
| Dec 31, 2024 | -1.60 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -8.22 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | -11.71 Mn |
| Jun 30, 2023 | -9.96 Mn |
| Mar 31, 2023 | -18.08 Mn |
| Dec 31, 2022 | -20.95 Mn |
| Sep 30, 2022 | -25.52 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -34.56 Mn |
| Sep 30, 2021 | -42.02 Mn |
| Jun 30, 2021 | -44.24 Mn |
| Mar 31, 2021 | -47.07 Mn |